The study, which resulted from experiments conducted with blood samples in laboratories, concluded that while a single dose vaccination has advantages, the benefits provided by a second immunisation may be well worth the inconvenience.
Nathaniel Landau, virologist at New York University’s Grossman School of Medicine, who led the study, told The New York Times: “The message we wanted to give was not that people shouldn’t get the Johnson & Johnson vaccine, but we hope that in the future, it will be boosted with either another dose of Johnson & Johnson or boosted with Pfizer or Moderna.”
Mr Landau and his team analysed blood samples of 17 people who had been immunised with two doses of an mRNA vaccine and 10 people with one dose of the Johnson & Johnson vaccine.
The Johnson & Johnson vaccine started out with a lower efficacy than the mRNA vaccine and showed a bigger drop in efficacy against the Delta and Lambda variants.
READ MORE: Covid HORROR: US doctor tells ‘young, begging’ unvaccinated patients ‘it’s too late’